PFE - Pfizer Inc.

Price: -- -- | CONSENSUS: Hold DETAILS | PRICE TARGET: $28.14 DETAILS

Stock News

Down 55%, Should You Buy the Dip on Pfizer?

Pfizer's stock price rocketed higher during the coronavirus pandemic. The shares have since plunged amid a key drug failure and approaching patent cliffs.

Jan 19, 2026 03:24 PM • fool.com

MoneyShow's Best Investment Ideas For 2026: Part 7

MoneyShow presents top investment ideas for 2026 from their contributors. This year's edition presents a mix of metals plays, financial stocks, deep value names, high-octane growth and tech...

Jan 19, 2026 02:20 PM • seekingalpha.com

What to Expect From Pfizer's Non-Oncology Business in Q4?

PFE's Q4 outlook centers on Eliquis growth, softer COVID-19 sales and steady demand for key non-oncology drugs ahead of earnings.

Jan 19, 2026 10:06 AM • zacks.com

Investing $10,000 in Each of These 5 Ultra-High-Yield Dividend Stocks Could Generate Over $3,700 in Passive Income in 2026

These five stocks offer dividend yields of up to 9.4%. They represent different sectors, including communication services, energy, financials, healthcare, and real estate.

Jan 18, 2026 04:44 AM • fool.com

Pfizer Inc. $PFE Stock Position Raised by Aviance Capital Partners LLC

Aviance Capital Partners LLC grew its holdings in Pfizer Inc. (NYSE: PFE) by 41.6% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission....

Jan 18, 2026 03:47 AM • defenseworld.net

The Best Dividend Stocks to Buy in 2026 and Hold Forever -- Including Pfizer (PFE) and United Parcel Service (UPS)

All three of these companies are well established, with solid growth prospects. Each faces some struggles, but all are paying shareholders to wait for stronger results.

Jan 17, 2026 08:53 AM • fool.com

Pfizer: Rebound Has Just Started

Pfizer has outperformed the S&P 500 since my previous call, driven by improving fundamentals and renewed share price momentum. Positive developments around the pipeline support long-term financial...

Jan 16, 2026 01:08 PM • seekingalpha.com

Pfizer: The Most Intriguing Value Play Of 2026

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV +...

Jan 15, 2026 08:58 AM • seekingalpha.com

Pfizer (PFE) Ascends While Market Falls: Some Facts to Note

In the latest trading session, Pfizer (PFE) closed at $25.56, marking a +1.63% move from the previous day.

Jan 14, 2026 06:46 PM • zacks.com

PFE Market Cap Falls More Than $7B in a Month: How to Play the Stock

Pfizer shares fall nearly 5% in a month after weak 2026 guidance, sparking debate over buying the dip or staying cautious.

Jan 14, 2026 08:45 AM • zacks.com

Inside Pfizer's Oncology Performance Ahead of Q4 Results

PFE's oncology results should reflect steady growth from Seagen ADCs and key brands, offset by pricing and competitive pressures.

Jan 13, 2026 08:55 AM • zacks.com

First Look: Fed Probe, Bank Cap Shock, Gold Soars, Deals

Stock News DOJ subpoenas Fed chair spark backlash: Federal prosecutors served grand jury subpoenas to Jerome Powell over testimony on Fed HQ renovations, prompt

Jan 13, 2026 07:38 AM • gurufocus.com

Pfizer's Patent Cliff, Rising Debt, And The Fight To Stay A Buy

Pfizer remains a 'Buy' at current low valuation multiples, but faces significant headwinds from an impending patent cliff through 2030. Pfizer's top-line growth is challenged by steep declines in...

Jan 13, 2026 06:11 AM • seekingalpha.com

Pfizer Inc. (NYSE:PFE) Given Consensus Rating of “Hold” by Analysts

Pfizer Inc. (NYSE: PFE - Get Free Report) has been given an average recommendation of "Hold" by the twenty brokerages that are presently covering the firm, MarketBeat Ratings reports. One analyst...

Jan 13, 2026 02:14 AM • defenseworld.net

Pfizer CEO plans for soaring consumer market for obesity drugs akin to Viagra

Pfizer is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug Viagra in 1998, CEO Albert Bourla said on Monday.

Jan 12, 2026 06:43 PM • reuters.com

Pfizer Inc. (PFE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026 03:16 PM • seekingalpha.com

Tempus Shares Jump After Strong Preliminary 2025 Results

Tempus AI (TEM) shares rose about 10% on Monday after the company filed preliminary, unaudited results showing roughly $1.27 billion in 2025 revenue.The filing

Jan 12, 2026 01:35 PM • gurufocus.com

Tempus AI Stock Soars After Posting Triple-Digit Diagnostics Growth

Tempus AI (NASDAQ: TEM) stock rose after releasing preliminary Q4 and 2025 results, with revenue of $1.27B in 2025 and $367M in Q4.

Jan 12, 2026 05:47 AM • feeds.benzinga.com

Bristlecone Advisors LLC Has $1.26 Million Stock Holdings in Pfizer Inc. $PFE

Bristlecone Advisors LLC lowered its stake in shares of Pfizer Inc. (NYSE: PFE) by 34.7% during the third quarter, according to the company in its most recent filing with the Securities and...

Jan 12, 2026 04:00 AM • defenseworld.net

Pfizer's BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal BREAKWATER trial, evaluating BRAFTOVI® (encorafenib)...

Jan 10, 2026 10:00 AM • businesswire.com